7
Participants
Start Date
September 30, 2010
Primary Completion Date
February 28, 2011
Study Completion Date
February 28, 2011
Bortezomib
1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
Panobinostat
20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
Masonic Cancer Center, University of Minnesota, Minneapolis
Collaborators (2)
Novartis Pharmaceuticals
INDUSTRY
Millennium Pharmaceuticals, Inc.
INDUSTRY
Masonic Cancer Center, University of Minnesota
OTHER